Announcements Trials
Browse Landscape

Status

Completed 6Unknown 2Recruiting 2Terminated 1No longer available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Neuroblastoma 1

Interventions

TIC10 compound 23-Iodobenzylguanidine 2tucatinib 1rindopepimut 1pembrolizumab 1pegfilgrastim 1paclitaxel-Angiopep-2 conjugate 1omburtamab I-131 1mogamulizumab 1gallium maltolate 1fluorodopa F 18 1efineptakin alfa 1avapritinib 1Vorinostat 1Potassium Iodide 1OKN 007 1Ketoconazole 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Fenretinide 1Cancer Vaccines 1Adjuvants, Immunologic 1ABT-414 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × pegfilgrastim × CNS × Clear all
NCT03649438 2024-12-11

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

University of Texas Southwestern Medical Center

No longer available
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡